Human Reproduction, Vol. 18, No. 2, 299-304,
February 2003
© 2003 European Society of Human Reproduction and Embryology
Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial
1 Reproductive Medicine Unit, 2 Department of Clinical Biochemistry, 3 Department of Biostatistics and 4 Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India
5 To whom correspondence should be addressed at: Reproductive Medicine Unit, Christian Medical College, Vellore, Tamil Nadu, India 632004. e-mail: rmu{at}cmcvellore.ac.in
BACKGROUND: Recognition of the importance of insulin resistance in clomiphene-resistant women with polycystic ovary syndrome (PCOS) has led to the use of insulin sensitizers. METHODS: A randomized, controlled trial was conducted to compare efficacy of sequential treatment with metformin and clomiphene citrate with conventional gonadotrophins. Sixty clomiphene-resistant women with PCOS were randomized to two groups (n = 30 each), using computer-generated tables. Group I received metformin for 6 months, followed by ovulation induction with clomiphene citrate; group II received hMG for ovulation induction. Hormonal profiles were evaluated at the onset and after completion of treatment. RESULTS: There was no significant difference in pregnancy rates between the two groups (16.7 versus 23.3%). In group I, there was a significant improvement in menstrual function and ovulation after treatment (40%, P < 0.001; and 46.7%, P < 0.001), with a significant decrease in fasting insulin levels (P < 0.05). There were no changes in other biochemical parameters. The ovulation rate in group II was 43.3%, with a high drop-out rate. The cost-effective analysis for medications per pregnancy in group I was US$ 71 ± 3 versus US$ 277 ± 171 in group II. CONCLUSIONS: Sequential treatment with metformin and clomiphene citrate is an effective and safe option for clomiphene-resistant women with PCOS.
Key words: insulin resistance/insulin sensitizer/metformin/PCOS
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Endocr. Rev., February 1, 2009; 30(1): 1 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Moll, F. van der Veen, and M. van Wely The role of metformin in polycystic ovary syndrome: a systematic review Hum. Reprod. Update, November 1, 2007; 13(6): 527 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J.C. Eijkemans, S. Polinder, A. G.M.G.J. Mulders, J. S.E. Laven, J.D. F. Habbema, and B. C.J.M. Fauser Individualized cost-effective conventional ovulation induction treatment in normogonadotrophic anovulatory infertility (WHO group 2) Hum. Reprod., October 1, 2005; 20(10): 2830 - 2837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Homburg Clomiphene citrate--end of an era? a mini-review Hum. Reprod., August 1, 2005; 20(8): 2043 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palomba, F. Orio Jr., L. G. Nardo, A. Falbo, T. Russo, D. Corea, P. Doldo, G. Lombardi, A. Tolino, A. Colao, et al. Metformin Administration Versus Laparoscopic Ovarian Diathermy in Clomiphene Citrate-Resistant Women with Polycystic Ovary Syndrome: A Prospective Parallel Randomized Double-Blind Placebo-Controlled Trial J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4801 - 4809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.J. Glueck, N. Goldenberg, J. Pranikoff, M. Loftspring, L. Sieve, and P. Wang Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy Hum. Reprod., June 1, 2004; 19(6): 1323 - 1330. [Abstract] [Full Text] [PDF]
|
|